Verseau Therapeutics
Auburndale, US · Founded 2017 · Delaware corporation · 1 known investors
Verseau develops cancer immunotherapies based on macrophage repolarization, converting immuno-suppressive M2 macrophages into pro-inflammatory M1 macrophages to trigger an immune response against tumors. The company uses a human-based discovery engine to identify targets regulating macrophage biology, with lead programs targeting PSGL-1 and VSIG4.
BiotechHealthtech
Founders & leadership
WC
Walter CaponeExecutive
CB
Christine BuntExecutive
DA
Daniel AndersonNamed on SEC filing
Board
RL
Robert LangerBoard director
JC
Jong ChangBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.3M disclosed across 1 round · 2017
▶$4.3MraisedMar 2017 · 5 investors · Other Health CareRule 506(b)
▶$4.3MraisedMar 2017 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Daniel AndersonExecutive Officer, Director, Promoter
- Walter CaponeExecutive Officer
- Robert LangerDirector, Promoter
- Jong ChangDirector
- Christine BuntExecutive Officer, Director
- Offering amount
- $11.4M
- Amount sold
- $4.3M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapVeratx6 shared keywordsVera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.
Vivace Therapeutics3 shared keywordsVivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.
Edgewise Therapeutics3 shared keywordsEdgewise Therapeutics develops novel therapeutics for serious cardiovascular muscle diseases, including hypertrophic cardiomyopathy (HCM) and heart failure. The company focuses on drug development targeting cardiac muscle for patients with life-limiting cardiovascular conditions.
Solu3 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Verseau Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Verseau Therapeutics do?
- Verseau develops cancer immunotherapies based on macrophage repolarization, converting immuno-suppressive M2 macrophages into pro-inflammatory M1 macrophages to trigger an immune response against tumors. The company uses a human-based discovery engine to identify targets regulating macrophage biology, with lead programs targeting PSGL-1 and VSIG4.
- Who are Verseau Therapeutics's investors?
- Verseau Therapeutics's investors include 20/20 HealthCare Partners LLC.
- How much funding has Verseau Therapeutics raised?
- Verseau Therapeutics has disclosed $4.3M raised across 1 round.
- Where is Verseau Therapeutics headquartered?
- Verseau Therapeutics is headquartered in Auburndale, US.